The ADA has released its 2023 guidelines. There are a significant number of impacts on medication therapy, and in this post I will outline my most important takeaways. I was also recently catching up with my friend and fellow pharmacist, Derek Borkowski who is the...
Drug interactions don’t come to the top of my mind when I see GLP-1 agonists in use. We are fortunate that they do not have a lot of significant interactions, but I don’t think you should forget about them altogether. I’ve provided a list below of my...
On May 13, 2022, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Mounjaro (tirzepatide), a once-weekly injection for the treatment of type 2 diabetes mellitus (T2DM). Pathophysiology of Type 2 Diabetes Mellitus Incretins are the...
The American Diabetes Association released their 2022 Diabetes Guidelines update. While I wouldn’t call the changes earth-shattering, there are some items in relation to pharmacotherapy that I feel are really important to note. The patient population that I work...
